New naloxone nasal spray at least doubles the dose
The Food and Drug Administration today approved a naloxone hydrochloride nasal spray to treat opioid overdoses that delivers 8 milligrams of naloxone, up from 2 mg or 4 mg in previously approved products.
“Addressing the opioid crisis is a top priority for the FDA, and we will continue our efforts to increase access to naloxone and place this important medicine in the hands of those who need it most,” said Patrizia Cavazzoni, M.D., director of FDA’s Center for Drug Evaluation and Research.
Related News Articles
Headline
The Department of Health and Human Services has delegated the Centers for Medicare & Medicaid Services certain statutory authorities to exclude individuals…
Headline
Multiple changes to transparency in coverage requirements for insurers were finalized Oct. 5 by the Departments of the Treasury, Labor, and Health and Human…
Headline
The House Ways and Means Committee July 1 voted along party lines to advance a bill, H.R. 9504, the Tax-Exempt Hospitals Transparency Act, that would add…
Headline
The Department of Health and Human Services published an interim final rule May 7 to delay compliance dates for entities receiving federal financial assistance…
Headline
The Centers for Medicare & Medicaid Services and the Food and Drug Administration April 23 announced a new pathway to expedite access to certain FDA-…
Headline
The Department of Justice April 20 published an interim final rule in the Federal Register to delay compliance dates for certain regulatory requirements…